Biomedical subjects

S Menacherry

Publications and source records attributed to S Menacherry.

6 recordsLinked to original sources

PubMed1998

Quantitation of TNP-470 and its metabolites in human plasma: sample handling, assay performance and stability.

A selective and sensitive assay for the determination of TNP-470 and two of its metabolites, AGM-1883 and M-II, in human plasma was developed. The assay involved liquid-liquid extraction followed by analysis using high-performance liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry. Because TNP-470 is most stable in a pH of 4-5, an acidification procedure was utilized to prevent degradation of TNP-470 during sample collection which involved acidifying the whole blood sample collected with 5 mg of citric acid per ml of blood. Liquid-liquid extraction using an organic solvent mixture was chosen over solid-phase extraction to minimize the degradation of TNP-470 during solvent evaporation.

Acetamides↗

PubMed1997

Analytical method development for the simultaneous quantitation of dexmedetomidine and three potential metabolites in plasma.

Dexmedetomidine, a novel alpha 2-adrenergic receptor agonist, is being developed as an anesthetic adjunct for perioperative use. An assay method has been developed for the sensitive quantitation of dexmedetomidine and three metabolites in plasma: MPV-1305, MPV-1306 and MPV-1709. The method involves solid-phase extraction (C18 cartridge) of dexmedetomidine and metabolites followed by a two-step derivatization. The first step utilized BF3-MeOH to simultaneously mask a primary alcohol in MPV-1305 and a carboxylic acid in MPV-1306. The second step applied PFB-Cl to derivatize the imidazole ring for sensitive detection of these compounds by GC-negative chemical ionization MS at pg/ml concentrations. MPV-1709 was not derivatized in the process and was detected by GC-positive chemical ionization MS. Optimization of extraction and derivatization is discussed. The method is suitable for quantitation of dexmedetomidine, MPV-1305, MPV-1306 and MPV-1709 over concentration ranges of 0.1, 40, 0.5-100, 0.5-100 and 1.0-500 ng/ml, respectively. The method showed excellent specificity, linearity and sensitivity and is useful for profiling the pharmacokinetic disposition of these compounds.

Adrenergic alpha-Agonists↗

PubMed1997

Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function.

OBJECTIVE: To study the effect of renal impairment on the pharmacokinetics of sertindole. METHODS: A single 4 mg oral dose of sertindole was given to normal subjects (n = 6) and subjects with various degrees of impaired renal function (n = 18) classified into mild, moderate, and severe/hemodialysis based on their creatinine clearance). The relationships between the pharmacokinetic parameters and the degree of renal impairment were investigated using regression analysis with creatinine clearance as an explanatory variable along with body weight. Subjects were also genotyped for CYP2D6-A or 2D6-B mutations. RESULTS: The mean CL/f and t1/2 values of sertindole ranged from 14 to 31 1.h-1 and from 73 to 93 h, respectively, and were not significantly related to creatinine clearances. There was no indication of any influence of creatinine clearance on the fraction of sertindole (0.994-0.995) binding to plasma proteins. The total fraction of the sertindole dose removed by dialysis was less than 0.1% Subjects with B/B genotype (n = 2) for CYP2D6 were associated with a distinctly lower clearance of sertindole (6.3 vs 25.3 1.h-1) than subjects with wt/wt genotype for CYP2D6. CONCLUSIONS: Since the pharmacokinetics of sertindole are unchanged by renal impairment, dosage adjustment does not appear to be necessary for subjects with various degrees of renal insufficiency or subjects with renal failure requiring hemodialysis.

Adult↗

PubMed1992

In vivo calibration of microdialysis probes for exogenous compounds.

Several approaches for calibrating microdialysis probes for exogenous compounds in vivo are described which avoid the error introduced by in vitro calibration. These methods are based on establishing a steady state of the exogenous compound by a continuous (zero-order) iv infusion. The steady-state concentration is estimated by three methods that directly determine the in vivo concentration. The methods are (a) extrapolation of dialysate concentrations at various flow rates to the concentration at zero flow, (b) dialysis with concentrations of analyte added to the perfusion medium above and below the expected concentration to determine the concentration at no net flux across the membrane, and (c) dialysis at a very slow perfusion rate (57 nL/min) where the recovery is expected to be better than 90%. Using these approaches, the recovery for cocaine in the brain was found to be (8.9 +/- 0.68)%, as compared to an in vitro recovery of (5.1 +/- 0.18)% at 24 degrees C and (7.4 +/- 0.18)% at 37 degrees C, at a perfusion rate of 1.2 microL/min through a 0.3- X 2-mm microdialysis probe. The in vivo concentration of cocaine in the rat brain for an intravenous dose of 0.3 mg/kg per min was found to be 17.1 +/- 1.3 microM.

Animals↗

PubMed1991

Analysis of 2-DG autoradiograms using image-averaging and image-differencing procedures for systems-level description of neurobehavioral function.

Computer assisted 2-deoxyglucose (2-DG) autoradiography has been used to provide functional maps of areas of altered neural activity related to changes in an animal's behavior or state. The standard procedure for comparison of autoradiograms between different treatment groups has been to take measurement samples from predefined neuroanatomical regions and to average these across brains to attain statistical sensitivity for detecting treatment effects. Unfortunately, when sampling is restricted to predefined areas, important topographic information is lost along with the ability to reveal an unexpected change in neural activity. To preserve the rich topographical detail of metabolic information and to enhance the capacity to uncover novel areas of altered metabolic activity, we have developed a system for averaging entire images from 2-DG autoradiograms and for comparing the average images from two experimental groups by creating an image of differences. This procedure does not rely on sampling only preselected regions, but still allows statistical comparisons between experimental groups. The procedures we describe can be readily and inexpensively adapted for use in individual laboratories and are based on modifications of preexisting image analysis software. We show that, when average and difference images are created using standardized protocols for sectioning brain tissue and editing section images, they are impressively resolved and realistic and can serve as effective topographic descriptions of group differences in neural activity of functional and behavioral relevance.

Animals↗

PubMed1991

Differences in the pharmacokinetics of cocaine in naive and cocaine-experienced rats.

Enhanced cocaine concentrations in brain and blood observed after an intraperitoneal challenge dose in rats exposed to cocaine for 10 days by subcutaneous administration are traced to a change in the absorption process from the site of an intraperitoneal injection to general circulation. This conclusion is reached by three sets of corroborating results: (a) Adipose tissue of rats treated for 10 days with repeat subcutaneous injections of cocaine did not reveal a buildup of cocaine in sufficient concentrations to account for the twofold increase in brain and blood concentrations seen during intraperitoneal administration; (b) administration of the drug by an intravenous route after 10-day cocaine treatment did not show a significant difference between treatment and control groups; (c) nonlinear regression on the intravenous and intraperitoneal data sets using a two-compartment open model indicated a difference in the absorption process but not in the metabolic and blood-brain transfer processes.

Absorption↗